Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Preventive Medicine》 2018-10
Add to Favorite Get Latest Update

Meta-analysis of protective efficacy of oral pentavalent human-bovine reassortant rotavirus live-attenuated vaccine

HU Yu;CHEN Ya-ping;LIANG Hui;WANG Ying;Department of Immunization Program,Zhejiang Provincial Center for Disease Control and Prevention;  
Objective To evaluate the protective efficacy(VE) of oral pentavalent human-bovine reassortant rotavirus live-attenuated vaccine(PRV). Methods We searched China Biology Medicine disc, China National Knowledge Infrastructure,Wanfang Database, National Center for Biotechnology Information and Cochrane Library about VE of PRV. Pooled estimates of odds ratio(OR) or relative risk(RR) of the incidence rates of rotavirus gastroenteritis and the vaccine efficacy(VE) were calculated according to the socio-economic development level and match of vaccine strains with pandemic strains,specifically.Results Five studies were included. In the highly developed countries,VE was 94%(95%CI:84%-98%) against homotypic strains, 82%(95% CI: 70%-89%) against partly heterotypic strains, 82%(95% CI: 70%-89%) against single-antigen vaccine type strains,and 75%(95%CI:47%-88%) against single-antigen non-vaccine type strains. In the middle developed countries, VE was 37%(95% CI: 10%-56%) against partly heterotypic strains, 71%(95% CI: 60%-78%) against single-antigen vaccine type strains, and 76%(95% CI: 61%-85%) against single-antigen non-vaccine type strains.Conclusion PRV can reduce the incidence of rotavirus gastroenteritis. The VE of PRV is related to the socio-economic development level and match of vaccine strains with pandemic strains.
【CateGory Index】: R392
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved